BIOLASE MAINTAINS GROWTH MOMENTUM AS FIRST QUARTER REVENUE INCREASED 25% YEAR OVER YEAR
LAKE FOREST, Calif., May 12, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the first quarter ended March 31, 2022.
2022 First Quarter and Recent Highlights
- Total revenue was $10.2 million, up 25% year over year
- U.S. laser sales increased 43% year over year and U.S. consumable sales increased 35% year over year, driven by increased procedures using BIOLASE lasers
- International laser sales increased 15% year over year, while international consumable sales remained consistent
- Higher average selling price and sales volumes resulted in a 47% gross margin for the quarter, an increase of 13 percentage points year over year
- Continued momentum with new customers and dental specialists with 81% of U.S. Waterlase sales coming from new customers and 65% of U.S. Waterlase sales coming from dental specialists
- Waterlase Exclusive Trial Program success rate increased to above 50% YTD, highlighting success of this program
- Maintained a healthy balance sheet with cash and cash equivalents of approximately $22 million on March 31, 2022
"Our continued strong performance in the first quarter reflects positive momentum on several fronts," commented John Beaver, president and chief executive officer. "During the quarter we saw continued progress with our Waterlase Exclusive Trial Program, as our success rate has surpassed 50% year to date. This initiative, along with the launch of our specialist academies for endodontists, periodontists, pediatric dentists, and dental hygienists, generated increased adoption of our laser technology in the U.S. this quarter with 81% of our sales coming from new customers and 65% of sales coming from dental specialists. Additionally, we had 14 territory managers exceed quota this quarter, which is significant given that this is historically our softest quarter.
"With only between 7% and 8% of the U.S. dental community currently using dental lasers, we are confident that we can leverage the enhanced capabilities of our dental lasers to drive further adoption and become the new standard of care. With every one percentage point increase in market adoption of laser technology in the U.S. alone, we estimate it will generate an additional $50 million in revenue for BIOLASE, assuming we maintain our current 60% market share. With our strong start to the year, and the continued success of our sales initiatives, we believe we are well positioned for continued revenue growth in 2022."
2022 First Quarter Financial Results
Net revenue for the first quarter of 2022 was $10.2 million, an increase of 25% year over year. U.S. laser revenue was $4.0 million for the first quarter of 2022, up 43% when compared to U.S. laser revenue of $2.8 million for the first quarter of 2021. U.S. consumables and other revenue for the first quarter of 2022, which consists of revenue from consumable products such as disposable tips, increased 35% compared to the first quarter of 2021. Outside the U.S., laser revenue increased 15% to $2.3 million for the first quarter of 2022 compared to $2.0 million for the first quarter of 2021, and consumables and other revenue remained consistent year over year at $0.9 million.
Gross margin for the first quarter of 2022 improved significantly to 47%, compared to 34% for the first quarter of 2021. The higher gross margin reflects the increase in revenue relative to the Company's fixed costs as well as higher average U.S. selling prices of its lasers. Total operating expenses were $8.9 million for the first quarter of 2022 compared to $8.8 million for the first quarter of 2021. Operating loss for the first quarter of 2022 was $4.2 million, compared to an operating loss of $6.1 million in the first quarter of 2021.
The Company maintained a healthy balance sheet and had cash and cash equivalents of $21.6 million on March 31, 2022. The Company believes it has sufficient financial resources to execute its near and long-term growth strategies.
Net Loss and Adjusted EBITDA
The reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's Adjusted EBITDA and Adjusted EBITDA per share.
Net loss for the first quarter of 2022 was $4.8 million compared to a net loss of $6.9 million for the first quarter of 2021. When adjusted for the reverse stock split, net loss per share for the quarter was $0.77 compared to $1.28 for the first quarter of 2021. Adjusted EBITDA loss for the first quarter of 2022 was $3.9 million compared with Adjusted EBITDA loss of $5.3 million for the first quarter of 2021. When adjusted retrospectively for the reverse stock split, adjusted EBITDA per share for the quarter was $0.64 compared to $0.97 for the first quarter of 2021.
2022 Second Quarter and Full Year Revenue Guidance
Based on currently available information and the continued operating momentum the Company has experienced in the first quarter, BIOLASE is anticipating second quarter net revenue to exceed $10.5 million, which would represent growth of at least 15% year over year. The Company continues to expect full year net revenue to increase at least 10% from 2021 levels.
Conference Call Information
BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the first quarter ended March 31, 2022 and to answer questions. To access the live call, dial 1-877-317-6789 (U.S.) or +1 412-317-6789 (International) and ask to join the BIOLASE earnings call.
A live and archived webcast of the conference call will be accessible on the BIOLASE Investor Relations page. In addition, a phone replay will be available approximately two hours following the end of the call, and it will remain available for one week. To access the call replay dial 1-877-344-7529 or +1 412-317-0088 (International) and enter replay passcode: 3445539.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 301 patented and 32 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth and beliefs regarding its financial resources. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
Tables to Follow
|
BIOLASE, INC. | ||||||||
|
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||
|
(Unaudited, in thousands, except per share data) | ||||||||
|
Three Months Ended |
||||||||
|
March 31, |
||||||||
|
2022 |
2021 |
|||||||
|
Net revenue |
$ |
10,166 |
$ |
8,116 |
||||
|
Cost of revenue |
5,437 |
5,375 |
||||||
|
Gross profit |
4,729 |
2,741 |
||||||
|
Operating expenses: |
||||||||
|
Sales and marketing |
4,814 |
3,553 |
||||||
|
General and administrative |
2,577 |
3,358 |
||||||
|
Engineering and development |
1,544 |
1,803 |
||||||
|
Loss on patent litigation settlement |
— |
89 |
||||||
|
Total operating expenses |
8,935 |
8,803 |
||||||
|
Loss from operations |
(4,206) |
(6,062) |
||||||
|
Loss on foreign currency transactions |
(120) |
(204) |
||||||
|
Interest expense, net |
(433) |
(575) |
||||||
|
Non-operating loss, net |
(553) |
(779) |
||||||
|
Loss before income tax provision |
(4,759) |
(6,841) |
||||||
|
Income tax provision |
(17) |
(60) |
||||||
|
Net loss |
(4,776) |
(6,901) |
||||||
|
Other comprehensive loss items: |
||||||||
|
Foreign currency translation adjustments |
(41) |
(148) |
||||||
|
Comprehensive loss |
$ |
(4,817) |
$ |
(7,049) |
||||
|
Net loss |
$ |
(4,776) |
$ |
(6,901) |
||||
|
Deemed dividend on convertible preferred stock |
(217) |
(532) |
||||||
|
Net loss attributable to common stockholders |
$ |
(4,993) |
$ |
(7,433) |
||||
|
Net loss per share attributable to common stockholders: |
||||||||
|
Basic and Diluted |
$ |
(0.81) |
$ |
(1.38) |
||||
|
Shares used in the calculation of net loss per share: |
||||||||
|
Basic and Diluted |
6,159 |
5,383 |
||||||
|
BIOLASE, INC. | ||||||||
|
CONSOLIDATED BALANCE SHEETS | ||||||||
|
(Unaudited, in thousands, except per share data) | ||||||||
|
March 31, |
December 31, |
|||||||
|
2022 |
2021 |
|||||||
|
ASSETS |
||||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ |
21,606 |
$ |
29,972 |
||||
|
Restricted cash |
203 |
203 |
||||||
|
Accounts receivable, less allowance of $2,236 and $2,154 as of March 31, 2022 and |
5,180 |
4,238 |
||||||
|
Inventory |
14,611 |
12,929 |
||||||
|
Prepaid expenses and other current assets |
2,183 |
2,012 |
||||||
|
Total current assets |
43,783 |
49,354 |
||||||
|
Property, plant, and equipment, net |
1,244 |
1,067 |
||||||
|
Goodwill |
2,926 |
2,926 |
||||||
|
Right of use asset |
2,058 |
1,717 |
||||||
|
Other assets |
231 |
220 |
||||||
|
Total assets |
$ |
50,242 |
$ |
55,284 |
||||
|
LIABILITIES, REDEEMABLE PREFERRED STOCK AND |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ |
4,643 |
$ |
3,309 |
||||
|
Accrued liabilities |
6,027 |
8,276 |
||||||
|
Deferred revenue, current portion |
2,442 |
2,259 |
||||||
|
Total current liabilities |
13,112 |
13,844 |
||||||
|
Deferred revenue |
303 |
329 |
||||||
|
Warranty accrual |
512 |
521 |
||||||
|
Non current term loans, net of discount |
13,666 |
13,603 |
||||||
|
Non current operating lease liability |
1,662 |
1,449 |
||||||
|
Other liabilities |
387 |
330 |
||||||
|
Total liabilities |
29,642 |
30,076 |
||||||
|
Redeemable preferred stock: |
||||||||
|
Series G Preferred stock, par value $0.001 per share |
— |
— |
||||||
|
Total redeemable preferred stock |
— |
— |
||||||
|
Stockholders' equity: |
||||||||
|
Series F Preferred stock, par value $0.001 per share |
— |
34 |
||||||
|
Common stock, par value $0.001 per share |
155 |
154 |
||||||
|
Additional paid-in capital |
293,419 |
293,177 |
||||||
|
Accumulated other comprehensive loss |
(664) |
(623) |
||||||
|
Accumulated deficit |
(272,310) |
(267,534) |
||||||
|
Total stockholders' equity |
20,600 |
25,208 |
||||||
|
Total liabilities, redeemable preferred stock and stockholders' equity |
$ |
50,242 |
$ |
55,284 |
||||
|
BIOLASE, INC. | ||||||||
|
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
|
(Unaudited, in thousands) | ||||||||
|
Three Months Ended |
||||||||
|
March 31, |
||||||||
|
2022 |
2021 |
|||||||
|
Cash Flows from Operating Activities: |
||||||||
|
Net loss |
$ |
(4,776) |
$ |
(6,901) |
||||
|
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: |
||||||||
|
Depreciation and amortization |
117 |
85 |
||||||
|
Provision for bad debts |
84 |
(106) |
||||||
|
Provision for sales returns |
60 |
90 |
||||||
|
Inventory write-offs and disposals |
— |
(20) |
||||||
|
Amortization of discount on lines of credit |
24 |
42 |
||||||
|
Amortization of debt issuance costs |
43 |
95 |
||||||
|
Patent litigation mark-to-market |
— |
89 |
||||||
|
Stock-based compensation |
209 |
928 |
||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
(1,085) |
(193) |
||||||
|
Inventory |
(1,682) |
(700) |
||||||
|
Prepaid expenses and other current assets |
(186) |
558 |
||||||
|
Accounts payable and accrued liabilities |
(986) |
(488) |
||||||
|
Deferred revenue |
157 |
22 |
||||||
|
Net cash and cash equivalents used in operating activities |
(8,021) |
(6,499) |
||||||
|
Cash Flows from Investing Activities: |
||||||||
|
Purchases of property, plant, and equipment |
(304) |
(8) |
||||||
|
Net cash and cash equivalents used in investing activities |
(304) |
(8) |
||||||
|
Cash Flows from Financing Activities: |
||||||||
|
Proceeds from the issuance of common stock, net of offering costs |
— |
13,292 |
||||||
|
Payments of equity offering costs |
— |
(6) |
||||||
|
Proceeds from the exercise of common stock warrants |
— |
16,539 |
||||||
|
Net cash and cash equivalents provided by financing activities |
— |
29,825 |
||||||
|
Effect of exchange rate changes |
(41) |
(148) |
||||||
|
(Decrease) increase in cash, cash equivalents and restricted cash |
(8,366) |
23,170 |
||||||
|
Cash, cash equivalents and restricted cash, beginning of period |
30,175 |
17,876 |
||||||
|
Cash, cash equivalents and restricted cash, end of period |
$ |
21,809 |
$ |
41,046 |
||||
|
Supplemental cash flow disclosure: |
||||||||
|
Cash paid for interest |
$ |
377 |
$ |
448 |
||||
|
Cash received for interest |
$ |
10 |
$ |
14 |
||||
|
Cash paid for income taxes |
$ |
26 |
$ |
10 |
||||
|
Cash paid for operating leases |
$ |
66 |
$ |
66 |
||||
|
Non-cash settlement of liability |
$ |
— |
$ |
510 |
||||
|
Non-cash right-of-use assets obtained in exchange for lease obligation |
$ |
444 |
$ |
— |
||||
|
Deemed dividend on preferred stock |
$ |
217 |
$ |
532 |
||||
Non-GAAP Financial Measures
In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. ("GAAP"), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents.
Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation and amortization, loss on patent litigation settlement, stock-based and other non-cash compensation, and allowance for doubtful accounts. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
|
BIOLASE, INC. | ||||||||
|
Reconciliation of GAAP Net Loss to Adjusted EBITDA and | ||||||||
|
GAAP Net Loss Per Share to Adjusted EBITDA Per Share | ||||||||
|
(Unaudited, in thousands, except per share data) | ||||||||
|
Three Months Ended |
||||||||
|
March 31, |
||||||||
|
2022 |
2021 |
|||||||
|
GAAP net loss attributable to common stockholders |
$ |
(4,993) |
$ |
(7,433) |
||||
|
Deemed dividend on convertible preferred stock |
217 |
532 |
||||||
|
GAAP net loss |
$ |
(4,776) |
$ |
(6,901) |
||||
|
Adjustments: |
||||||||
|
Interest expense, net |
433 |
575 |
||||||
|
Income tax provision |
17 |
60 |
||||||
|
Depreciation and amortization |
117 |
85 |
||||||
|
Change in allowance for doubtful accounts |
84 |
(106) |
||||||
|
Loss on patent litigation settlement |
— |
89 |
||||||
|
Stock-based and other non-cash compensation |
209 |
928 |
||||||
|
Adjusted EBITDA |
$ |
(3,916) |
$ |
(5,270) |
||||
|
GAAP net loss attributable to common stockholders |
$ |
(0.81) |
$ |
(1.38) |
||||
|
Deemed dividend on convertible preferred stock |
0.04 |
0.10 |
||||||
|
GAAP net loss per share, basic and diluted |
$ |
(0.77) |
$ |
(1.28) |
||||
|
Adjustments: |
||||||||
|
Interest expense, net |
0.07 |
0.11 |
||||||
|
Income tax provision |
— |
0.01 |
||||||
|
Depreciation and amortization |
0.02 |
0.02 |
||||||
|
Change in allowance for doubtful accounts |
0.01 |
(0.02) |
||||||
|
Loss on patent litigation settlement |
— |
0.02 |
||||||
|
Stock-based and other non-cash compensation |
0.03 |
0.17 |
||||||
|
Adjusted EBITDA per share, basic and diluted |
$ |
(0.64) |
$ |
(0.97) |
||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-maintains-growth-momentum-as-first-quarter-revenue-increased-25-year-over-year-301546535.html
SOURCE BIOLASE, Inc.
Released May 12, 2022
